Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.31: DETAILS OF IMPORTED AND INDIGENOUS MATERIALS, SPARE PARTS, CHEMICALS AND COMPONENTS CONSUMED PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 VALUE % OF TOTAL CONSUMPTION FOR THE YEAR ENDED 31 MARCH 2014 VALUE % OF TOTAL CONSUMPTION Raw material and chemicals Imported 8,677 39% 8,119 37% Indigenous 13,807 61% 13,799 63% 22,484 21,918 Stores, spares and other materials Imported 811 22% 514 17% Indigenous 2,944 78% 2,521 83% 3,755 3,035 2.32: CIF VALUE OF IMPORTS PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Raw materials 11,512 9,611 Capital equipment (including spares and components) 1,973 2,348 13,485 11,959 2.33: EARNINGS IN FOREIGN CURRENCY PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Exports on FOB basis 74,146 74,059 Interest on loan to subsidiaries 187 90 Service income and license fees 390 1,495 Guarantee commission 132 176 Others 15 187 74,870 76,007 2.34: EXPENDITURE IN FOREIGN CURRENCY PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Legal and professional 1,892 1,358 Bio-studies expenses 1,368 1,001 Interest on loans 657 604 Others 8,606 9,685 12,523 12,648 150
Standalone Financial Statements Annual Report 2014 - 15 NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.35: HEDGES OF FOREIGN CURRENCY RISK AND DERIVATIVE FINANCIAL INSTRUMENTS The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, British pounds sterling, Russian roubles and Euros, and foreign currency debt in U.S. dollars, Russian roubles and Euros. The Company uses forward contracts, option contracts and swap contracts (derivatives) to mitigate its risk of changes in foreign currency exchange rates. Further, the Company also uses non derivative financial instruments as part of its foreign currency exposure risk mitigation strategy. In respect of the aforesaid foreign exchange derivative contracts, the Company has recorded, as part of foreign exchange gains and losses, a net gain of ` 1,040 and a net loss of ` 297 for the years ended 31 March 2015 and 2014, respectively. Hedges of highly probable forecasted transactions The Company classifies its derivative contracts that hedge foreign currency risk associated with highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classified in the statement of profit and loss as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion is immediately recorded in the statement of profit and loss. The Company also designates certain non derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for the hedge of foreign currency risk associated with highly probable forecasted transactions and, accordingly, applies cash flow hedge accounting for such relationships. Re-measurement gain/loss on such non derivative financial liabilities is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classified in the statement of profit and loss as revenue in the period corresponding to the occurrence of the forecasted transactions. In respect of the aforesaid hedges of highly probable forecasted transactions, the Company has recorded, in reserves and surplus, a net gain of ` 51 and a net loss of ` 407 for the years ended 31 March 2015 and 2014, respectively. The Company also recorded, as part of revenue, a net gain of ` 810 and a net loss of ` 946 during the years ended 31 March 2015 and 2014, respectively. The net carrying amount of the Company’s “hedging reserve” was a gain of ` 46 as at 31 March 2015, as compared to a loss of ` 5 as at 31 March 2014. The table below summarises the periods when the forecasted cash flows associated with hedging instruments that are classified as cash flow hedges, are expected to occur: PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Cash flows in U.S. Dollars (figures in equivalent rupee millions) Not later than one month 1,250 1,797 Later than one month and not later than three months 5,625 3,595 Later than three months and not later than six months 6,875 5,392 Later than six months and not later than one year 3,750 5,992 17,500 16,776 Cash flows in Roubles (figures in equivalent rupee millions) Not later than one month 27 - Later than one month and not later than three months 54 - Later than three months and not later than six months 81 - Later than six months and not later than one year 161 - 323 - 151
Page 1 and 2:
ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4:
Our Brand We are in the business of
Page 5 and 6:
Corporate Overview Annual Report 20
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Statutory Reports • Business Resp
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Statutory Reports • Management Di
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Statutory Reports • Corporate Gov
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Statutory Reports • Additional Sh
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Statutory Reports • Board’s Rep
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102: Statutory Reports • Board’s Rep
Page 111 and 112: Standalone Financial Statements Ann
Page 151: Standalone Financial Statements Ann
Page 165 and 166: Consolidated Financial Statements A
Page 203 and 204:
Consolidated Financial Statements A
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Notice Annual Report 2014 - 15 NOTI
Page 229 and 230:
E-Voting Annual Report 2014 - 15 IN
Page 231:
Dr. Reddy’s Laboratories Limited
Page 235 and 236:
The future belongs, not to those wh
show all

Good Health Can’t Wait.

Create successful ePaper yourself

Delete template?

Save as template?